Literature DB >> 19794513

Parkinson disease. Nonmotor symptoms in Parkinson disease: the PRIAMO study.

Ronald F Pfeiffer1.   

Abstract

Nonmotor symptoms are assuming an increasingly important place in the constellation of clinical traits that characterize Parkinson disease. A multicenter survey of patients with Parkinson disease highlights the prevalence of these symptoms. The findings indicate that further research into the pathophysiology and treatment of nonmotor symptoms is warranted.

Entities:  

Mesh：

Year:  2009        PMID： 19794513     DOI： 10.1038/nrneurol.2009.156

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


  7 in total

1.  Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology.

Authors:  Heiko Braak; Rob A I de Vos; Jürgen Bohl; Kelly Del Tredici
Journal:  Neurosci Lett       Date:  2005-12-05       Impact factor: 3.046

2.  Non-recognition of depression and other non-motor symptoms in Parkinson's disease.

Authors:  L M Shulman; R L Taback; A A Rabinstein; W J Weiner
Journal:  Parkinsonism Relat Disord       Date:  2002-01       Impact factor: 4.891

Review 3.  Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology.

Authors:  L L Edwards; E M Quigley; R F Pfeiffer
Journal:  Neurology       Date:  1992-04       Impact factor: 9.910

4.  Frequency of bowel movements and the future risk of Parkinson's disease.

Authors:  R D Abbott; H Petrovitch; L R White; K H Masaki; C M Tanner; J D Curb; A Grandinetti; P L Blanchette; J S Popper; G W Ross
Journal:  Neurology       Date:  2001-08-14       Impact factor: 9.910

5.  The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease.

Authors:  Paolo Barone; Angelo Antonini; Carlo Colosimo; Roberto Marconi; Letterio Morgante; Tania P Avarello; Eugenio Bottacchi; Antonino Cannas; Gabriella Ceravolo; Roberto Ceravolo; Giulio Cicarelli; Roberto M Gaglio; Rosa M Giglia; Francesco Iemolo; Michela Manfredi; Giuseppe Meco; Alessandra Nicoletti; Massimo Pederzoli; Alfredo Petrone; Antonio Pisani; Francesco E Pontieri; Rocco Quatrale; Silvia Ramat; Rosanna Scala; Giuseppe Volpe; Salvatore Zappulla; Anna Rita Bentivoglio; Fabrizio Stocchi; Giorgio Trianni; Paolo Del Dotto
Journal:  Mov Disord       Date:  2009-08-15       Impact factor: 10.338

6.  Fatigue in Parkinson's disease.

Authors:  J Friedman; H Friedman
Journal:  Neurology       Date:  1993-10       Impact factor: 9.910

7.  Fatigue in Parkinson's disease patients.

Authors:  Joseph H Friedman
Journal:  Curr Treat Options Neurol       Date:  2009-05       Impact factor: 3.598
  7 in total
  4 in total

1.  Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson's disease.

Authors:  Juan Carlos Gómez-Esteban; Beatriz Tijero; Johanne Somme; Roberto Ciordia; Koldo Berganzo; Idoia Rouco; Jose Luis Bustos; Maria Antonia Valle; Elena Lezcano; Juan J Zarranz
Journal:  J Neurol       Date:  2010-10-19       Impact factor: 4.849

2.  The combination of homocysteine and C-reactive protein predicts the outcomes of Chinese patients with Parkinson's disease and vascular parkinsonism.

Authors:  Limin Zhang; Junqiang Yan; Yunqi Xu; Ling Long; Cansheng Zhu; Xiaohong Chen; Ying Jiang; Lijuan Yang; Lianfang Bian; Qing Wang
Journal:  PLoS One       Date:  2011-04-27       Impact factor: 3.240

3.  Contra-Directional Expression of Serum Homocysteine and Uric Acid as Important Biomarkers of Multiple System Atrophy Severity: A Cross-Sectional Study.

Authors:  Dan Chen; Xiaobo Wei; Jing Zou; Rui Wang; Xu Liu; Xiaofeng Xu; Jianjun Lu; Zhanhang Wang; Beisha Tang; Brian Wang; Kunlin Jin; Qing Wang
Journal:  Front Cell Neurosci       Date:  2015-07-06       Impact factor: 5.505

4.  Reduced serum levels of triglyceride, very low density lipoprotein cholesterol and apolipoprotein B in Parkinson's disease patients.

Authors:  Qiang Wei; Honghao Wang; Yanghua Tian; Fangcheng Xu; Xianwen Chen; Kai Wang
Journal:  PLoS One       Date:  2013-09-26       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.